HomeAI · summaries
Storia in 8 fonti
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer
CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to…
- ·
fiercepharma.com
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study,…
- ·
economictimes.indiatimes.com
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study
The study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have little to no detectable cancer in the…
- ·
morningstar.com
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long…
- ·
medpagetoday.com
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survival
- ·
independent.co.uk
Prostate cancer breakthrough as drug combo gives patients a powerful new chance
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery, substantially increased the chances of…
- ·
endpoints.news
J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain
As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.
- ·
medicalxpress.com
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone…